Centredoc acquires the patent analytics business from IPStudies

IPSTUDIES

CENTREDOC and IPStudies today announced that CENTREDOC has acquired the patent analytics assets and operations from IPStudies as of Jan 1st, 2022. The transferred assets include the internationally renowned patent landscapes and patent monitoring services developed by IPStudies since 2014 on the revolutionary CRISPR genome editing technology. IPStudies customers will benefit from the latest advances in patent multi-categorization and multi-source feeds as developed by Centredoc with the breakthrough RAPID5 patent monitoring suite.

Corinne Le Buhan, CEO of IPStudies, said: “CENTREDOC has many years of experience in serving patent monitoring and business intelligence to a diversity of industries in Europe and will bring the IPStudies offering to the next level. With this transfer, we assure the sustainable growth of our patent analytics services demand, as biotech and medtech C-levels are more and more combining patent data with scientific publications and business intelligence to develop their IP strategy plans. ” Harald Jenny, CEO of CENTREDOC, said: “We are delighted to integrate the excellent patent analytics knowhow and life sciences expertise of IPStudies with a strong perspective of further growth through our latest RAPID5 tools and associated services.”

For more information:
Corinne LeBuhan, +41 79 787 57 46
Harald Jenny, +41 79 435 11 80

About CRISPR
About RAPID5